The U.S. Drug Enforcement Administration’s (DEA) announcement on March 18, 2026, temporarily placing bromazolam into Schedule I of the Controlled Substances Act, serves as a stark reminder of the rapidly evolving landscape of synthetic drug regulation. This action, targeting a novel benzodiazepine, is not an isolated incident but rather a signal of an accelerating trend in the scheduling of emerging synthetic compounds. For healthcare facilities, pharmacies, and law enforcement agencies, this dynamic environment introduces significant challenges in maintaining secure and compliant drug destruction processes. Read More >
